-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Downgrades PTC Therapeutics to Sector Perform, Raises Price Target to $91

Benzinga·12/01/2025 14:22:59
Listen to the news
RBC Capital analyst Brian Abrahams downgrades PTC Therapeutics (NASDAQ:PTCT) from Outperform to Sector Perform and raises the price target from $82 to $91.